Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536234 | 1.00 | THRA (0.76) | THRATHRB | |
| SCHEMBL4358608 | 1.00 | THRA (0.76) | THRATHRB | |
| SCHEMBL7953072 | 0.92 | THRA (0.67) | THRATHRB | |
| SCHEMBL4353275 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL5618648 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL7958049 | 0.89 | THRA (0.80) | THRATHRB | |
| SCHEMBL5618676 | 0.89 | THRA (0.61) | THRATHRB | |
| SCHEMBL6099194 | 0.89 | THRA (0.61) | THRATHRB | |
| SCHEMBL5618670 | 0.89 | THRA (0.82) | THRATHRB | |
| SCHEMBL7953070 | 0.89 | THRA (0.82) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6989402-B1 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2006-01-24 | — | — | US | claimed |
| US-20050282872-A1 | Novel thyroid receptor ligands and method II | HANGELAND JON | 2005-12-22 | — | — | US | claimed |
| EP-1144370-A2 | THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2001-10-17 | — | — | EP | claimed |
| WO-2000039077-A2 | THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2000-07-06 | — | — | WO | claimed |
| WO-2009080835-A1 | THYROMIMETRIC COMPOUNDS IN TREATMENT OF DISEASE RELATED TO SONIC HEDGEHOG SIGNALLING | KARO BIO AB (SE) | 2009-07-02 | — | — | WO | disclosed |
| US-7288571-B2 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2007-10-30 | — | — | US | disclosed |
| US-6989402-B1 | Thyroid receptor ligands and method II | KARO BIO AB (SE) | 2006-01-24 | — | — | US | disclosed |
| US-20050282872-A1 | Novel thyroid receptor ligands and method II | HANGELAND JON | 2005-12-22 | — | — | US | disclosed |
| EP-1144370-A2 | THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000039077-A2 | THYROID RECEPTOR LIGANDS | KARO BIO AB (SE) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282872-A1 | Novel thyroid receptor ligands and method II | TSHR, THRB, THRA | THRA 3/4885THRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.